Comparable stake leader
James Alexander Cunliffe Foster
SEC ownership of Virax Biolabs Group Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001885827.
Disclosed value leader
James Alexander Cunliffe Foster
Comparable rows
2/4
Latest evidence
30 Jun 2026
- Public ticker
- VRAX on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
James Alexander Cunliffe Foster
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
2 of 4
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
James Alexander Cunliffe Foster
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001885827
- Issuer location
- Lanarkshire, United Kingdom
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Virax Biolabs Group Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
James Alexander Cunliffe ...
Disclosed value leader
James Alexander Cunliffe ...
Comparable rows
2/4
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 8.3%
2 rows are not safely comparable across share classes.
13D/G row: James Alexander Cunliffe Foster
Quick read
James Alexander Cunliffe Foster leads the comparable SEC ownership view at 8.3%.
2 of 4 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens James Alexander Cunliffe Foster's linked filing trail.
Comparable ownership
Top 2
James Alexander Cunliffe Foster
8.3%
ARMISTICE CAPITAL, LLC
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-4 of 4 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| James Alexander Cunliffe Foster |
13D/G
3/4/5
James Foster · Chief Executive Officer
|
8.3%
|
$232,199
368,570 shares
|
+$30,634 | 31 Mar 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$170,041
1,000,239 shares
|
+$29,976 | 31 Mar 2026 |
| JANE STREET GROUP, LLC |
13F
Company
|
—
class O/S missing
|
$77,572
26,385 shares
|
— | 30 Jun 2026 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$12
4 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 22 Aug 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to Virax Biolabs Group Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
James Alexander Cunliffe Foster
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James Alexander Cunliffe Foster | Chief Executive Officer | $63,357 | Mixed | 18 Mar 2026 | ||
| Iain David Miller | Director | Mixed | 18 Mar 2026 | |||
| Jason Davis | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Evan Michael Norton | Director | Mixed | 18 Mar 2026 | |||
| Nigel William McCracken | Chief Operating Officer, Director | Mixed | 18 Mar 2026 | |||
| Nelson M. Haight | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Virax Biolabs Group Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James Alexander Cunliffe Foster | VRAX | Ordinary Shares | 0 | 287,987 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.